This inventor holds 17 USPTO granted patents, plus 1 CIPO patent. Top assignee: Eisai Company, Limited. Active years: 1986-1999.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Ibaraki, JP (1986 - 1987)
- Tsuchiura, JP (1989 - 1997)
- Bethesda, MD (US) (1996 - 1997)
- Maryland, MD (US) (1994 - 1999)
Company Filing History:
Years Active: 1986-1999
Title: Hiroo Ogura: Innovator in Cyclic Amide Derivatives
Introduction
Hiroo Ogura is a prominent inventor based in Tsuchiura, Japan. He has made significant contributions to the field of pharmaceuticals, holding a total of 17 patents. His work primarily focuses on cyclic amide derivatives and their applications in treating diseases related to central choline functions.
Latest Patents
One of Ogura's latest patents involves cyclic amide derivatives, defined by a specific chemical formula. This derivative is pharmacologically effective in preventing and treating diseases due to insufficiency of the central choline functions. Another notable patent is for a piperidine derivative, which also includes pharmacologically acceptable salts. These innovations highlight his commitment to advancing medical science through chemical research.
Career Highlights
Hiroo Ogura has built a successful career at Eisai Company, Limited, where he has been instrumental in developing new pharmaceutical compounds. His expertise in cyclic amide compounds has positioned him as a key figure in the industry, contributing to the advancement of therapeutic options for various health conditions.
Collaborations
Ogura has collaborated with notable colleagues, including Hachiro Sugimoto and Norio Karibe. These partnerships have fostered a collaborative environment that enhances innovation and research within the pharmaceutical sector.
Conclusion
Hiroo Ogura's contributions to the field of pharmaceuticals through his patents and collaborations underscore his role as a leading inventor. His work continues to impact the medical community positively, paving the way for new treatments and advancements in healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
